Advertisement
Advertisement
TXG
10x Genomics, Inc. Class A Common Stock
23.68
USDSponsored
-1.00
-4.05%
May 22, 15:59 UTC -4
Closed
Pre-Market
24.23
+0.55
+2.32%
TXG Earnings Reports
Positive Surprise Ratio
TXG beat 15 of 27 last estimates.
56%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$147.96M
/-$0.25
Implied change from Q1 26 (Revenue/ EPS)
-1.91%
/+150.00%
Implied change from Q2 25 (Revenue/ EPS)
-14.43%
/-189.29%
10x Genomics, Inc. Class A Common Stock earnings per share and revenue
On May 07, 2026, TXG reported earnings of -0.10 USD per share (EPS) for Q1 26, beating the estimate of -0.29 USD, resulting in a 66.04% surprise. Revenue reached 150.84 million, compared to an expected 147.82 million, with a 2.05% difference. The market reacted with a -3.66% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 16 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 147.96 million USD, implying an increase of 150.00% EPS, and decrease of -1.91% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Doximity, Inc.
Report Date
May 13, 2026 For Q4 26
Estimate
$0.28
Actual
$0.26
Surprise
-9.97%
Doximity, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
$0.28
Actual
$0.26
Surprise
-9.97%
Heartflow, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.19
Actual
-$0.23
Surprise
-20.10%
CapsoVision, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.15
Surprise
-12.02%
Nyxoah SA Ordinary Shares
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.36
Surprise
+27.03%
MDxHealth SA Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-9.68%
Insight Molecular Diagnostics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.12
Surprise
+55.01%
Neuraxis, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.19
Actual
-$0.18
Surprise
+7.12%
Heartbeam, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.12
Surprise
+14.77%
P3 Health Partners Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$3.57
Actual
$0.32
Surprise
+108.95%
FAQ
What were 10x Genomics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, 10x Genomics, Inc. Class A Common Stock reported EPS of -$0.10, beating estimates by 66.04%, and revenue of $150.84M, 2.05% above expectations.
How did the market react to 10x Genomics, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -3.66%, changed from $22.42 before the earnings release to $21.60 the day after.
When is 10x Genomics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for 10x Genomics, Inc. Class A Common Stock's next earnings report?
Based on 16
analysts, 10x Genomics, Inc. Class A Common Stock is expected to report EPS of -$0.25 and revenue of $147.96M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement